LABORATORY RESEARCH Canonical Wnt Signaling Regulates Hematopoiesis in a Dosage-Dependent Fashion To investigate whether canonical Wnt signaling regulates hematopoiesis in a dosage-dependent fashion, researchers analyzed the effect of different mutations in the Adenomatous polyposis coli gene, a negative modulator of the canonical Wnt pathway. [Cell Stem Cell] Abstract The Ribosome-Related Protein, SBDS, Is Critical for Normal Erythropoiesis Investigators asked whether SBDS, which is mutated in most Shwachman-Diamond syndrome patients, is critical for erythroid development. [Blood] Abstract Effect of Nucleophosmin1 Haploinsufficiency on Hematopoietic Stem Cells Mice genetically engineered to harbor heterozygous loss of nucleophosmin1 were shown to have a mild myelodysplastic syndrome-like phenotype characterized by dyserythropoiesis and dysplastic megakaryocytes with macrocytic anemia, but without significant cytopenias or alterations in lineage commitment. [Leukemia] Abstract Impaired Functionality and Homing of Fancg-Deficient Hematopoietic Stem Cells Scientists have examined the role of the nuclear Fanconi Anemia core complex gene Fancg in the functionality of hematopoietic stem cells. [Hum Mol Genet] Abstract MicroRNA-150-Regulated Vectors Allow Lymphocyte-Sparing Transgene Expression in Hematopoietic Gene Therapy Here, researchers have investigated the potential of microRNA-150 target sequences to specifically suppress gene expression in lymphocytes and thereby prevent transgene-induced lymphotoxicity. [Gene Ther] Abstract CLINICAL RESEARCH Induced Immune Tolerance for Kidney Transplantation In the current proof-of-concept study, 12 patients who received HLA-matched kidney transplants received a donor-cell infusion of highly enriched CD34+ hematopoietic progenitor cells mixed with CD3+ T cells, and a conditioning regimen of total lymphoid irradiation and anti–T-cell antibodies according to a protocol described in detail in a previous case report of the successful induction of tolerance. [N Engl J Med] Abstract | Press Release Phase I/II Study to Assess the Safety, Efficacy, and Pharmacokinetics of Barasertib (AZD1152) in Patients with Advanced Acute Myeloid Leukemia The primary objective of this Phase I/II two-part study was to determine the maximum-tolerated dose of the potent and selective Aurora B kinase inhibitor barasertib, in patients with newly diagnosed or relapsed acute myeloid leukemia. [Blood] Abstract Favorable Outcome in Infants with AML After Intensive First- and Second-Line Treatment: An AML-BFM Study Group Report Data indicates that intensive frontline and relapse acute myeloid leukemia (AML) treatment is feasible in infants, toxicities are manageable, and outcome is favorable. [Leukemia] Abstract |